{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-26-000003","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.427616+00:00","generated_at":"2026-05-16T01:43:56.556942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prothena posts Q4 2025 net loss $21.6M; full-year loss $244.1M; 2026 cash burn guide $50-55M","bullets":["Net loss $21.6M ($0.40 EPS) in Q4 vs $58.0M loss ($1.08 EPS) in Q4 2024; full-year loss $244.1M ($4.53 EPS).","Total revenue $21K in Q4 vs $2.1M a year ago; full-year revenue $9.7M vs $135.2M in 2024.","Cash & restricted cash $308.4M at Dec 31, 2025; no debt; shares outstanding ~53.8M.","2026 guidance: net cash used in ops $50-55M; year-end cash ~$255M; excludes up to $105M milestones.","Partners Roche, Novo Nordisk, BMS initiated Phase 3 trials for prasinezumab, coramitug, and BMS-986446."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-26-000003","json":"https://secwatch.observer/filing/0001559053-26-000003.json","markdown":"https://secwatch.observer/filing/0001559053-26-000003.md","text":"https://secwatch.observer/filing/0001559053-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000003/0001559053-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000003/prta-20260219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:43:56.556942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}